Press Releases September 3, 2026 07:30 AM

Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences

Structure Therapeutics Announces Participation in Major September Healthcare Investor Conferences

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
GPCR

Structure Therapeutics, a clinical-stage biopharmaceutical company focused on oral small molecule therapeutics for metabolic diseases, will participate in three leading healthcare investment conferences in September 2026, including Cantor Global Healthcare, Morgan Stanley Global Healthcare, and Bernstein’s Healthcare Forum. Management will hold fireside chats and one-on-one meetings, with webcast access available.

Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences
GPCR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Structure Therapeutics is showcasing its clinical-stage pipeline targeting metabolic diseases, particularly obesity, at major investor conferences.
  • The company leverages a next-generation structure-based drug discovery platform focused on GPCR targets to develop scalable oral therapies.
  • Participation at these conferences provides increased visibility to investors and stakeholders in the biotech and healthcare sectors.

SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in three upcoming healthcare conferences in September:

2026 Cantor Global Healthcare Conference
Date: Thursday, September 10
Format: Fireside chat and 1x1 meetings
Time: 3:55 – 4:25 PM EDT
Location: New York, NY

Morgan Stanley 24th Annual Global Healthcare Conference
Date: Wednesday, September 16
Format: Fireside chat and 1x1 meetings
Time: 10:45 – 11:20 AM EDT
Location: New York, NY

Bernstein’s 3rd Annual Healthcare Forum
Date: Wednesday, September 23
Format: Fireside Chat and 1x1 meetings
Time: 3:00 – 3:40 PM EDT
Location: New York, NY

The live and archived webcasts will be accessible from the company’s website at https://ir.structuretx.com/events-presentations/events and replays will be available for at least 90 days.

About Structure Therapeutics 
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com.

Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
[email protected]

Jennifer Robinson
Structure Therapeutics Inc.
[email protected]

Media:
Dan Budwick
1AB
[email protected]


Risks

  • Clinical-stage biopharmaceutical development carries inherent risks including clinical trial outcomes and regulatory approval challenges impacting the biotech sector.
  • The company's focus on novel oral small molecule therapeutics for obesity faces competitive and scientific uncertainties affecting metabolic disease treatment markets.
  • Market reactions to these presentations are uncertain and depend on the content and investor perception, which could influence stock volatility in the healthcare investment space.

More from Press Releases

Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call Sep 6, 2026 Verizon Waives Charges for Hurricane Lowell, Prepares Network in Hawai'i Sep 5, 2026 Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen Sep 4, 2026 Grupo Aeroportuario del Pacifico Reports a Passenger Traffic Increase in August 2026 of 0.5% Compared to 2025 Sep 4, 2026 Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference Sep 4, 2026